Porcilis® PCV M Hyo Emulsion for injection for pigs
Porcilis PCV M Hyo is used to protect pigs against two of the most important diseases in pigs - porcine circovirus associated diseases and enzootic pneumonia, caused by Mycoplasma hyopneumoniae.
- Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as wasting, weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
- Infection with the bacterium Mycoplasma hyopneumoniae in pigs is responsible for the development of enzootic pneumonia. Affected pigs have a dry cough and fail to thrive, with important consequences to their growth performance.
Presentation
Emulsion for injection. Homogenous white to nearly white emulsion after shaking.
Active ingredients
Per 2 ml dose:
- Porcine circovirus type 2 (PCV2) ORF2 subunit antigen > 2828 AU1
- Mycoplasma hyopneumoniae J strain inactivated > 2.69 RPU2
1Antigenic units as determined in the in vitro potency test (ELISA).
2Relative potency units defined against a reference vaccine.
Target species
Pigs for fattening
Indications for use
For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies).
Onset of immunity with single dose vaccination:
PCV2: 2 weeks after vaccination
M. hyopneumoniae: 4 weeks after vaccination.
Onset of immunity with two dose vaccination:
PCV2: 18 days after first vaccination
M. hyopneumoniae: 3 weeks after the second vaccination.
Duration of immunity (both vaccination schedules):
PCV2: 22 weeks after (the last) vaccination
M. hyopneumoniae: 21 weeks after (the last) vaccination
Withdrawal periods
Pigs – meat: zero days
Packaging
50, 100 and 200 ml
Legal category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: July 2024